Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD

Jia Qi Chen, MD, PhD

Zhejiang University School of Medicine

Zhejiang, China

IPC Jr. Councilor

Bio

In this edition of our Fellows Spotlight, we reconnect and catch up with 2018 IPC Fellow, Dr. Jia Qi Chen. Dr. Chen is a dermatologic fellow at the Second Affiliated Hospital of Zhejiang University School of Medicine. Holding a PhD in Dermatology from Zhejiang University, she completed her residency at the same institution. Dr. Chen is an accomplished lead author of three peer-reviewed manuscripts. Her expertise lies in investigating the pathogenesis of psoriasis, showcasing a dedicated focus in her dermatology education.

As a 2018 Fellow, she studied with IPC Councilor Dr. Curdin Conrad, MD, at the University Hospital of Lausanne (CHUV) in Switzerland and attended the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris. Dr. Chen now shares her reflections on the IPC International Fellowship Program experience and its impact on her career.

The IPC Fellowship Experience

Having Curdin Conrad as my mentor was such a stroke of luck! I spent a month at CHUV, in Lausanne, Switzerland. Dr. Conrad took me through his specialized clinic every week, demonstrating how he approaches patient care. His profound respect for patients left a lasting impression on me, shaping my approach as a dermatologist in the clinic. Additionally, I had around 15 days in his lab, providing me with a preliminary understanding of his research field.

“I owe a special thanks to the IPC Fellowship Program, as I believe I wouldn’t have secured the scholarship without its valuable support.” 

Post-Fellowship Achievements

Winning the Swiss Government Excellence Scholarship (FCS) for the academic year 2020/2021 was a significant achievement for me. Throughout that academic year, I spent an entire year in CHUV in Dr. Conrad’s lab, creating lasting memories. I owe a special thanks to the IPC Fellowship Program, as I believe I wouldn’t have secured the scholarship without its valuable support.

Applying Knowledge in the Field

During the program, I acquired valuable research skills, such as independently conducting FISH in situ. This year, I went further and applied for the National Natural Science Foundation of China. Fortunately, I secured a grant, which will significantly enhance my research on the pathogenesis of psoriasis, with a particular focus on pustular psoriasis.

Navigating Career Challenges

After the Fellowship, I encountered several career challenges. I vividly recall the nervous moments during the application for the FCS. Thankfully, Dr. Conrad provided support through communications and a stellar recommendation letter. This assistance alleviated my anxiety, and eventually, I received the good news!

Evolving Perspectives on the Industry

Biological agents have rapidly gained prominence worldwide, simplifying the treatment of moderate to severe psoriasis. However, this widespread use has introduced new challenges, such as paradoxical psoriasis. In our department, we’ve initiated using FACS to identify potential abnormal cytokines in patients’ lesions. This allows us to tailor treatment by selecting the appropriate biologics or small molecular inhibitors for each patient.

Advice for Future Fellowship Participants

Staying on-site for more than a month – no matter what – would be my top tip! It’s essential to connect with other professionals—it sparks fresh ideas, streamlines work, and clears up any misunderstandings. Being proactive during the program is also crucial, and trust me, the rewards will follow.

If you are a young dermatologist or researcher passionate about improving the lives of people with psoriasis and want to expand your horizons, consider applying to participate in IPC’s International Fellowship Program. Applications for the 2025 program will open in September 2024.

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

A grid of eight professionally dressed people, four men and four women—each an IPC Fellowship participant—in individual portrait photos, set against a colorful geometric background.
Clinical psoriasis management

Meet IPC’s 2026 International Fellows

Meet the 2026 IPC International Fellows, eight internationally selected clinicians and researchers advancing evidence-based psoriasis care and global collaboration through the International Psoriasis Council.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026